Abstract

Cardiac cells can adapt to pathological stress-induced energy crisis by shifting from fatty acid oxidation to glycolysis. However, the use of glucose-insulin-potassium (GIK) solution in patients undergoing cardiac surgery does not alleviate ischemia/reperfusion (I/R)-induced energy shortage. This indicates that insulin-mediated translocation of glucose transporter-4 (Glut-4) is impaired in ischemic hearts. Indeed, cardiac myocytes contain two intracellular populations of Glut-4: an insulin-dependent non-endosomal pool (also referred to as Glut-4 storage vesicles, GSVs) and an insulin-independent endosomal pool. Tumor susceptibility gene 101 (Tsg101) has been implicated in the endosomal recycling of membrane proteins. In this study, we aimed to examine whether Tsg101 regulated the sorting and re-distribution of Glut-4 to the sarcolemma membrane of cardiomyocytes under basal and ischemic conditions, using gain- and loss-of-function approaches. Forced overexpression of Tsg101 in mouse hearts and isolated cardiomyocytes could promote Glut-4 re-distribution to the sarcolemma, leading to enhanced glucose entry and adenosine triphosphate (ATP) generation in I/R hearts which in turn, attenuation of I/R-induced cardiac dysfunction. Conversely, knockdown of Tsg101 in cardiac myocytes exhibited opposite effects. Mechanistically, we identified that Tsg101 could interact and co-localize with Glut-4 in the sarcolemma membrane of cardiomyocytes. Our findings define Tsg101 as a novel regulator of cardiac Glut-4 trafficking, which may provide a new therapeutic strategy for the treatment of ischemic heart disease.

Highlights

  • The heart can adapt a variety of substrates in order to produce sufficient amounts of adenosine triphosphate (ATP) as energy to maintain effective contractile function [1,2,3,4]

  • Tumor susceptibility gene 101 (Tsg101) and Sarcolemma glucose transporter-4 (Glut-4) Levels Are Upregulated in Ischemic Hearts

  • Our results showed that did Tsg101 bind to Glut-4, but this association was further enhanced in both WT and TG hearts after ischemic injury (Figure 7I,J)

Read more

Summary

Introduction

The heart can adapt a variety of substrates in order to produce sufficient amounts of ATP as energy to maintain effective contractile function [1,2,3,4]. Strategies that enhance glucose uptake represent a promising approach to treat ischemic heart disease. Recent clinical and lab studies indicate that ischemia induces a reduction of intracellular pH, which in turn inhibits cardiac insulin signaling [9,10,11]. Multiple recent clinical trials testing the effects of glucose-insulin-potassium (GIK solution) on patients undergoing heart surgery have not yielded beneficial outcomes [12,13,14]. These studies suggest that insulin resistance in surgically induced I/R hearts remains a major hurdle in treating such patients

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call